|
|
|
10.12.25 - 18:31
|
Biogen Aktie: Analystenwarnung! HSBC sieht Risiko für Gewinne (Aktiencheck)
|
|
|
London (www.aktiencheck.de) - Biogen-Aktienanalyse von HSBC:
Die Analysten von HSBC stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) von "hold" auf "reduce" herab und setzen ein Kursziel von 143 USD (zuvor: 144 USD).
Die Herabstufung sei darauf zurückzuführen, dass Biogens "angeschlagene" Multiple-Sklerose-Sparte das Wachstum in anderen Bereichen überwiege. [mehr]...
|
|
|
|
|
10.12.25 - 15:03
|
Great Point Partners Acquires a Majority Stake in Lenis Group, a Full-Service Specialty Pharmaceutical Commercialization and Distribution Partner (Business Wire)
|
|
|
Former CEO of Biogen, Michel Vounatsos, Appointed Board Chairman of Lenis
GREENWICH, Conn. & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Great Point Partners (“GPP” or “the Firm”), a Greenwich-based private investment firm focused exclusively on the healthcare industry, today announced that it has acquired a majority stake in Lenis Group (“Lenis” or “the Company”), a fast-growing Slovenian-based full-service regional commercialization and distribution partner for niche and specialty Rx medicines in Central and Eastern Europe (“CEE”).
Founded in 2008, Lenis has become a trusted partner to biotechnology and pharmaceutical companies across the highly complex but rapidly growing CEE region, covering the entire product lifecycle – from early access and pre-launch, through launch and growth, to mature lifecycle management.
The Company is recognized for its strong compliance culture, market access and reimbursement capabilities, regulatory expertise, and high-quality medical and marketing functio...
|
|
|
|
|
10.12.25 - 10:48
|
Health Canada approves Biogen′s Zurzuvae for PPD treatment (PBR)
|
|
|
The once-daily oral therapy is administered as a 14-day course. Clinical trials demonstrated benefits from as early as day three, with significant symptom reduction by day 15, and
The post Health Canada approves Biogen's Zurzuvae for PPD treatment appeared first on Pharmaceutical Business review....
|
|
|
09.12.25 - 00:33
|
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer′s Disease Included in China′s Commercial Insurance Innovative Drug List (GlobeNewswire EN)
|
|
|
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China....
|
|
|
|
|
|
|
05.12.25 - 15:06
|
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting (Business Wire)
|
|
|
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life—
—Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and consistent with the ongoing Phase 3 EMPEROR study—
—Analysis of electroencephalogram (EEG) supports a disease-modifying mechanism of action—
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonu...
|
|
|
|
|
|
|
02.12.25 - 22:45
|
New Data Presented at the Clinical Trials on Alzheimer′s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF (PR Newswire)
|
|
|
TOKYO and CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest data......
|
|
|
|
|
|
|
01.12.25 - 13:36
|
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
|
|
|
– New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modification –
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.
Zorevunersen is an investigational antisense oligonucleotide currently being evaluated as a potential first-in-class medicine for the treatment of Dravet syndrome, a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures and significant cognitive and behavioral impairments. Data to be presented at AES are derived from four years ...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
